嵌合抗原受体t细胞治疗多发性骨髓瘤的研究进展

白血病·淋巴瘤 Pub Date : 2020-03-25 DOI:10.3760/CMA.J.CN115356-20191220-00265

Q. Lin, Yan Yan

{"title":"嵌合抗原受体t细胞治疗多发性骨髓瘤的研究进展","authors":"Q. Lin, Yan Yan","doi":"10.3760/CMA.J.CN115356-20191220-00265","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM. \n \n \nKey words: \nMultiple myeloma; Chimeric antigen receptor T-cell; B-cell maturation antigen; CD19","PeriodicalId":16246,"journal":{"name":"白血病·淋巴瘤","volume":"29 1","pages":"136-140"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress of chimeric antigen receptor T-cell therapy for multiple myeloma\",\"authors\":\"Q. Lin, Yan Yan\",\"doi\":\"10.3760/CMA.J.CN115356-20191220-00265\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM. \\n \\n \\nKey words: \\nMultiple myeloma; Chimeric antigen receptor T-cell; B-cell maturation antigen; CD19\",\"PeriodicalId\":16246,\"journal\":{\"name\":\"白血病·淋巴瘤\",\"volume\":\"29 1\",\"pages\":\"136-140\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"白血病·淋巴瘤\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.CN115356-20191220-00265\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"白血病·淋巴瘤","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN115356-20191220-00265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体T细胞（CAR-T）疗法在治疗血液肿瘤方面取得了突破性进展。靶向κ免疫球蛋白轻链、CD19和B细胞成熟抗原（BCMA）的CAR-T疗法已被用于治疗复发/难治性MM（RRMM）患者，抗BCMA CAR-T的效果最好。然而，BCMA的阴性或阳性复发导致短的无进展生存期（PFS），嵌合抗原受体（CAR）结构的改善靶向BCMA、双靶向CAR-T和CAR-T结合小分子药物等措施已成为CAR-T治疗RRMM的重点。关键词：多发性骨髓瘤；嵌合抗原受体T细胞；B细胞成熟抗原；CD19

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Progress of chimeric antigen receptor T-cell therapy for multiple myeloma

Chimeric antigen receptor T-cell (CAR-T) therapy has made a breakthrough in the treatment of hematological tumors. CAR-T therapy targeting kappa immunoglobulin light chain, CD19 and B-cell mature antigen (BCMA) have been used to treat relapsed/refractory MM (RRMM) patients, and the effect of anti-BCMA CAR-T is the best. However, the negative or positive recurrence of BCMA leads to a short progression-free survival (PFS), the improvement of the chimeric antigen receptor (CAR) structure targeted BCMA, dual-targeted CAR-T and CAR-T combined with small molecular drugs as well as other measures have become the focuses of CAR-T in the treatment of RRMM. Key words: Multiple myeloma; Chimeric antigen receptor T-cell; B-cell maturation antigen; CD19

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

白血病·淋巴瘤 Medicine-Oncology

自引率

0.00%

发文量

6278

期刊介绍： The JLL is a specialized academic journal that carries articles on hematological malignancies, and mainly about leukemia and lymphoma, involving the fields of medicine, chemistry, biology, etc. The purposes are to reflect the scientific results and the academic trends in the hematological malignancy field. It paid attention on both the basic research and clinical work, but more on the clinical side; on combining popularization with the raising of standards, but more on the raising of standards, in order to provide a field for exchanging experience, inspiring mutually and linking up information for those working for the basic research and clinical diagnosis and treatment in the field of leukemia and lymphoma. It is intended for high and middle ranking medical staffs.